Great find!
(like any cancer, they would need to do preclinical study and then human trials to confirm that Bisantrene is effective for treating Liver Cancer via an FTO pathway)
This just confirms that FTO is relevant for Liver Cancer.
Each one of these identified, increases the possibility that Bisantrene will eventually as an FTO-targeting agent achieve revenues at similar levels to Keytruda.
Current forecast for 2026 Keytruda sales around USD $25B.
Here's a list of all the indications Keytruda is now approved for. Currently 30.
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-23
-
- There are more pages in this discussion • 2,986 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.84 |
Change
0.080(4.56%) |
Mkt cap ! $312.7M |
Open | High | Low | Value | Volume |
$1.76 | $1.86 | $1.76 | $464.9K | 258.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5399 | $1.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.86 | 4243 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5399 | 1.835 |
1 | 25000 | 1.815 |
1 | 10000 | 1.800 |
1 | 8516 | 1.790 |
1 | 190 | 1.785 |
Price($) | Vol. | No. |
---|---|---|
1.860 | 4243 | 1 |
1.865 | 2690 | 1 |
1.880 | 866 | 1 |
1.890 | 6000 | 2 |
1.900 | 8590 | 3 |
Last trade - 16.10pm 24/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online